No Data
No Data
WHO Chief Tedros Says Mpox Vaccines Could Be Ready For Emergency Use Listing Within Two Weeks; Some Mpox Vaccines Expected To Arrive In Congo In The Next Few Days
Alnylam Says Typo In Presentation Misstated Heart Drug Benefit
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
Alnylam Falls After Full Data for Heart Drug That Can Rival Pfizer's
Amgen Unusual Options Activity For August 29
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know